Skip to content

ENDONOVO THERAPEUTICS, INC.

ENDV

CIK 0001528172

← back to feed
Revenue (TTM)
$145.22K
+85.2% YoY Q3 Dec 2023
Net Income (TTM)
$7.92M
−495.0% YoY Q3 Dec 2023
EPS Diluted (TTM)
−$0.01
Q3 Dec 2023
Gross Margin
93.9%
Q3 Dec 2023
Operating Margin
-1,811.2%
Q3 Dec 2023
Net Margin
5,457.0%
Q3 Dec 2023
Free Cash Flow (TTM)
−$885.87K
Q3 Dec 2023
Cash
$0
Q3 Dec 2023
Total Debt
$7.1M
Q3 Dec 2023
Shares Outstanding
318.75M sh
Q3 Dec 2023

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings